255 related articles for article (PubMed ID: 32869671)
1. The dawn of targeted therapies for triple negative breast cancer (TNBC): a snapshot of investigational drugs in phase I and II trials.
Huynh MM; Pambid MR; Jayanthan A; Dorr A; Los G; Dunn SE
Expert Opin Investig Drugs; 2020 Nov; 29(11):1199-1208. PubMed ID: 32869671
[TBL] [Abstract][Full Text] [Related]
2. The evolving management of metastatic triple negative breast cancer.
Malhotra MK; Emens LA
Semin Oncol; 2020 Aug; 47(4):229-237. PubMed ID: 32563561
[TBL] [Abstract][Full Text] [Related]
3. Triple negative breast cancer chemosensitivity and chemoresistance: current advances in biomarkers indentification.
Guestini F; McNamara KM; Ishida T; Sasano H
Expert Opin Ther Targets; 2016 Jun; 20(6):705-20. PubMed ID: 26607563
[TBL] [Abstract][Full Text] [Related]
4. cMET in triple-negative breast cancer: is it a therapeutic target for this subset of breast cancer patients?
Gaule PB; Crown J; O'Donovan N; Duffy MJ
Expert Opin Ther Targets; 2014 Sep; 18(9):999-1009. PubMed ID: 25084805
[TBL] [Abstract][Full Text] [Related]
5. Targeting triple negative breast cancer with histone deacetylase inhibitors.
Fedele P; Orlando L; Cinieri S
Expert Opin Investig Drugs; 2017 Nov; 26(11):1199-1206. PubMed ID: 28952409
[TBL] [Abstract][Full Text] [Related]
6. Update on the Treatment of Early-Stage Triple-Negative Breast Cancer.
Sharma P
Curr Treat Options Oncol; 2018 Apr; 19(5):22. PubMed ID: 29656345
[TBL] [Abstract][Full Text] [Related]
7. Targeted Therapies for Triple-Negative Breast Cancer.
Lyons TG
Curr Treat Options Oncol; 2019 Nov; 20(11):82. PubMed ID: 31754897
[TBL] [Abstract][Full Text] [Related]
8. Emerging drugs for the treatment of triple-negative breast cancer: a focus on phase II immunotherapy trials.
Hall PE; Schmid P
Expert Opin Emerg Drugs; 2021 Jun; 26(2):131-147. PubMed ID: 33870839
[No Abstract] [Full Text] [Related]
9. Targeting the PI3K/AKT/mTOR pathway in triple-negative breast cancer: a review.
Costa RLB; Han HS; Gradishar WJ
Breast Cancer Res Treat; 2018 Jun; 169(3):397-406. PubMed ID: 29417298
[TBL] [Abstract][Full Text] [Related]
10. The triple negative breast cancer drugs graveyard: a review of failed clinical trials 2017-2022.
Taurelli Salimbeni B; Corvaja C; Valenza C; Zagami P; Curigliano G
Expert Opin Investig Drugs; 2022 Nov; 31(11):1203-1226. PubMed ID: 36413823
[TBL] [Abstract][Full Text] [Related]
11. Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai X; Ni J; Beretov J; Graham P; Li Y
Cancer Lett; 2021 Jan; 497():100-111. PubMed ID: 33069769
[TBL] [Abstract][Full Text] [Related]
12. Sacituzumab govitecan: breakthrough targeted therapy for triple-negative breast cancer.
Weiss J; Glode A; Messersmith WA; Diamond J
Expert Rev Anticancer Ther; 2019 Aug; 19(8):673-679. PubMed ID: 31398063
[No Abstract] [Full Text] [Related]
13. Molecular subtyping and genomic profiling expand precision medicine in refractory metastatic triple-negative breast cancer: the FUTURE trial.
Jiang YZ; Liu Y; Xiao Y; Hu X; Jiang L; Zuo WJ; Ma D; Ding J; Zhu X; Zou J; Verschraegen C; Stover DG; Kaklamani V; Wang ZH; Shao ZM
Cell Res; 2021 Feb; 31(2):178-186. PubMed ID: 32719455
[TBL] [Abstract][Full Text] [Related]
14. Triple-Negative Breast Cancers: Systematic Review of the Literature on Molecular and Clinical Features with a Focus on Treatment with Innovative Drugs.
Diana A; Franzese E; Centonze S; Carlino F; Della Corte CM; Ventriglia J; Petrillo A; De Vita F; Alfano R; Ciardiello F; Orditura M
Curr Oncol Rep; 2018 Aug; 20(10):76. PubMed ID: 30128845
[TBL] [Abstract][Full Text] [Related]
15. Subtyping of triple-negative breast cancer: implications for therapy.
Abramson VG; Lehmann BD; Ballinger TJ; Pietenpol JA
Cancer; 2015 Jan; 121(1):8-16. PubMed ID: 25043972
[TBL] [Abstract][Full Text] [Related]
16. Targeted and immuno-biology driven treatment strategies for triple-negative breast cancer: current knowledge and future perspectives.
Fremd C; Jaeger D; Schneeweiss A
Expert Rev Anticancer Ther; 2019 Jan; 19(1):29-42. PubMed ID: 30351981
[No Abstract] [Full Text] [Related]
17. Homologous recombination deficiency and host anti-tumor immunity in triple-negative breast cancer.
Telli ML; Stover DG; Loi S; Aparicio S; Carey LA; Domchek SM; Newman L; Sledge GW; Winer EP
Breast Cancer Res Treat; 2018 Aug; 171(1):21-31. PubMed ID: 29736741
[TBL] [Abstract][Full Text] [Related]
18. Triple-negative breast cancer: advancements in characterization and treatment approach.
Hurvitz S; Mead M
Curr Opin Obstet Gynecol; 2016 Feb; 28(1):59-69. PubMed ID: 26694831
[TBL] [Abstract][Full Text] [Related]
19. Neoadjuvant therapy for triple-negative breast cancer: potential predictive biomarkers of activity and efficacy of platinum chemotherapy, PARP- and immune-checkpoint-inhibitors.
Garufi G; Palazzo A; Paris I; Orlandi A; Cassano A; Tortora G; Scambia G; Bria E; Carbognin L
Expert Opin Pharmacother; 2020 Apr; 21(6):687-699. PubMed ID: 32052646
[TBL] [Abstract][Full Text] [Related]
20. Ixazomib in combination with carboplatin in pretreated women with advanced triple-negative breast cancer, a phase I/II trial of the AGMT (AGMT MBC-10 trial).
Rinnerthaler G; Gampenrieder SP; Petzer A; Burgstaller S; Fuchs D; Rossmann D; Balic M; Egle D; Rumpold H; Singer CF; Bartsch R; Petru E; Melchardt T; Ulmer H; Mlineritsch B; Greil R
BMC Cancer; 2018 Nov; 18(1):1074. PubMed ID: 30400780
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
